EOM Pharmaceutical Holdings, Inc. (IMUC)
(Delayed Data from OTC)
$0.19 USD
-0.01 (-4.52%)
Updated Jun 13, 2024 03:00 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
EOM Pharmaceutical Holdings, Inc. [IMUC]
Reports for Purchase
Showing records 41 - 60 ( 90 total )
Company: EOM Pharmaceutical Holdings, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: EOM Pharmaceutical Holdings, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: EOM Pharmaceutical Holdings, Inc.
Industry: Medical - Biomedical and Genetics
ASCO Should Bring Clarity on ICT-107 Path Forward; Maintain Neutral
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: EOM Pharmaceutical Holdings, Inc.
Industry: Medical - Biomedical and Genetics
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: EOM Pharmaceutical Holdings, Inc.
Industry: Medical - Biomedical and Genetics
2013 Results; Awaiting Post-Hoc Analyses at ASCO; Maintain Neutral
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: EOM Pharmaceutical Holdings, Inc.
Industry: Medical - Biomedical and Genetics
Post Hoc Analyses Planned; Questions Remain; Maintain Neutral
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: EOM Pharmaceutical Holdings, Inc.
Industry: Medical - Biomedical and Genetics
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: EOM Pharmaceutical Holdings, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: EOM Pharmaceutical Holdings, Inc.
Industry: Medical - Biomedical and Genetics
We Were Wrong; For Now? Off Focus List; Rating to Neutral, Target to $2
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: EOM Pharmaceutical Holdings, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: EOM Pharmaceutical Holdings, Inc.
Industry: Medical - Biomedical and Genetics
Adding to Focus List; We''re Taking the ICT-107 Phase II Bet; Target to $9
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: EOM Pharmaceutical Holdings, Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: EOM Pharmaceutical Holdings, Inc.
Industry: Medical - Biomedical and Genetics
3Q13 Results; Get Ready! Phase II Data Soon; We Expect a Win
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: EOM Pharmaceutical Holdings, Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: EOM Pharmaceutical Holdings, Inc.
Industry: Medical - Biomedical and Genetics
2Q13 Results; Visibility Continues to Increase for ICT-107 Phase II
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: EOM Pharmaceutical Holdings, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: EOM Pharmaceutical Holdings, Inc.
Industry: Medical - Biomedical and Genetics
Pipeline Expands; Critical Catalyst Not Too Far Off; Reiterate Buy
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: EOM Pharmaceutical Holdings, Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: EOM Pharmaceutical Holdings, Inc.
Industry: Medical - Biomedical and Genetics
Randomized Phase II Cleared for Completion; Reiterate Buy
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: EOM Pharmaceutical Holdings, Inc.
Industry: Medical - Biomedical and Genetics
Healthcare - AVAglio Data Unimpressive; Cancer Vaccine Approaches Continue to Be Favored
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J